Download Files:
Products Details
Product Description
– YK-029A is an orally active inhibitor of mutant EGFR，targeting to both the T790M mutations (EGFRT790M) and exon 20 insertion of EGFR (EGFRex20ins). YK-029A exhibits significant antitumor activity，and results tumor regression in EGFRex20ins-driven PDX models[1].
Web ID
– HY-155537
Shipping
– Room temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C27H32N8O2
References
– [1]Liu B, et al. Discovery of YK-029A, a novel mutant EGFR inhibitor targeting both T790 M and exon 20 insertion mutations, as a treatment for NSCLC. Eur J Med Chem. 2023 Oct 5;258:115590.
CAS Number
– 2064269-82-3
Molecular Weight
– 500.60
SMILES
– C=CC(NC1=CC(NC2=NC=CC(C3=CN=C4C(C)=CC=CN43)=N2)=C(OC)C=C1N(CCN(C)C)C)=O
Clinical Information
– No Development Reported
Research Area
– Cancer
Solubility
– 10 mM in DMSO
Target
– EGFR
Pathway
– JAK/STAT Signaling;Protein Tyrosine Kinase/RTK
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
